By Joshua Kirby

 

Novartis AG said Thursday that it will invest $250 million in research against malaria and neglected tropical diseases, or NTDs.

As part of the five-year commitment, the Swiss drugmaker will invest $100 million to advance research and development of its NTS program, focusing on novel drug candidates for four disease, namely Chagas, visceral leishmaniasis, dengue fever and Cryptosporidium, which are all at varying stages of development.

Meanwhile, Novartis said it will invest $150 million to advance three novel drug candidates against malaria. The company will continue with activities to support the development of an optimized formulation for neonates and infants under 5 kilograms, for whom no treatment currently exists, Novartis said.

The investment commitment comes as Novartis endorses the Kigali Declaration amid the 26th Commonwealth Heads of Government Meeting in Rwanda.

The declaration aims to combat NTDs and deliver the targets set out in the World Health Organization's NTD Roadmap 2021-30, Novartis said.

 

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby

 

(END) Dow Jones Newswires

June 23, 2022 02:16 ET (06:16 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Set 2022 até Out 2022 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Out 2021 até Out 2022 Click aqui para mais gráficos Novartis.